Taylor Boyd

Corporate Officer/Principal at AVALO THERAPEUTICS, INC.

37 year

Health Technology

Consumer Services

Profile

Taylor Boyd is Chief Business Officer at Avalo Therapeutics, Inc. since 2025.
Former roles include Chief Business Officer & Executive VP at Abzena Ltd. and Investor Relations Contact at Oxford Biomedica Plc from 2022 to 2024.
Education includes graduate studies at Wake Forest University and undergraduate studies at North Carolina State University.

Taylor Boyd active positions

Companies	Position	Start
AVALO THERAPEUTICS, INC.	Corporate Officer/Principal	2025-09-30

All active positions of Taylor Boyd

Former positions of Taylor Boyd

Companies	Position	End
OXFORD BIOMEDICA PLC	Public Communications Contact	2023-12-31
ABZENA PLC	Corporate Officer/Principal	-

See the detail of Taylor Boyd's experience

Training of Taylor Boyd

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Taylor Boyd's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Oxford Biomedica Plc Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields	Health Technology
Wake Forest University Wake Forest University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
North Carolina State University North Carolina State University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Avalo Therapeutics, Inc. Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases	Health Technology
Abzena Ltd. Abzena Ltd. BiotechnologyHealth Technology Engages in discovery, development and manufactures biologics drugs	Health Technology